Full-Time

Pharmaceutical Sales

Neuroscience Long Term Care

Otsuka Pharmaceutical

Otsuka Pharmaceutical

1,001-5,000 employees

Global pharma maker of Abilify

Compensation Overview

$116k - $166.8k/yr

+ Incentive opportunity

Remote in USA + 1 more

More locations: San Antonio, TX, USA

In Person

Must reside within 50 miles of San Antonio and travel daily by car.

Bachelor's

Category
Sales & Account Management (1)
Required Skills
Patient Care

Get referred to Otsuka Pharmaceutical

See people who can refer or advise you

Requirements
  • A Bachelor's degree.
  • At least 2 years of pharmaceutical or medical device sales experience.
  • Must reside within a commutable distance of 50 miles from San Antonio.
  • Ability to travel is required, including daily field travel by car.
Responsibilities
  • Demonstrate a comprehensive understanding of the long-term care environment, including regulatory requirements, operational challenges, and the specific needs of residents, and use this knowledge to position solutions that add value to long-term care facilities.
  • Identify and cultivate strategic relationships with key decision-makers within long-term care facilities, such as administrators, directors of nursing, and pharmacy managers.
  • Develop and execute tailored communication and sales strategies aligned with each long-term care facility's operational demands, patient outcomes, and compliance objectives.
  • Provide detailed, on-label information aligned with product labeling, including complex on-label details in accordance with approved materials, while complying with regulatory standards.
  • Address product-access factors including local market payer coverage, co-pay options, prior authorization requirements, formulary placement, and availability expectations.
  • Offer established guidance on patient care, including system protocols, standards-of-care guidelines, discharge protocols, and published expert opinions.
  • Use virtual and digital tools, including webinars, virtual meetings, digital newsletters, and interactive online platforms, to engage customers.
  • Use competitive data and business reports, including sales data and promotional budgets, to track progress and uncover opportunities.
  • Apply territory and business-condition knowledge to establish near-term priorities for the territory business plan.
  • Respond compliantly to competitive threats and opportunities.
  • Educate office staff on payer guidelines and reimbursement procedures to increase product pull-through.
  • Effectively use promotional materials.
  • Maintain awareness of internal support-team resources and use them appropriately.
  • Apply market and industry knowledge to overcome objections and influence prescribing habits during office calls.
  • Identify territory professional groups for networking and exposure to potential key opinion leaders.
  • Build relationships with key office and practice personnel, take responsibility for follow-through, and provide accurate information in response to account needs.
  • Deliver effective and balanced office calls and sales presentations using approved marketing materials and technical references, such as studies and package inserts, while demonstrating product and competitive knowledge.
Desired Qualifications
  • Essential experience in pharmaceutical sales, healthcare management, or a related field.
  • Experience within long-term care and/or central nervous system healthcare is highly advantageous.
  • At least 4 years of experience in a sales role with healthcare providers, ideally representing multiple products.
  • A thorough understanding of the long-term care environment, including regulatory requirements, operational challenges, and the clinical needs of long-term care residents.
  • Proven ability to build and maintain strategic relationships with key stakeholders within long-term care facilities.
  • Ability to thrive in an ambiguous environment undergoing transformation.
  • A proven track record in coaching, training, and mentoring peers or others.
  • Excellent verbal and written communication skills to effectively convey complex information and engage with healthcare providers and decision-makers.
  • A commitment to ethical business practices, an understanding of regulatory standards, and the ability to execute business activities in compliance with company policies and guidance.
Otsuka Pharmaceutical

Otsuka Pharmaceutical

View

Otsuka Pharmaceutical develops and markets medicines and health products worldwide, including prescription drugs and nutraceutical beverages. Its product lineup ranges from pharmaceutical treatments such as Abilify (an antipsychotic) to consumer health drinks like Pocari Sweat, which helps replenish electrolytes. Abilify works as a psychiatric medication used to treat conditions such as schizophrenia and bipolar disorder, while Pocari Sweat is an ion-replacement beverage designed to restore minerals and fluids after activity or heat. The company differentiates itself through a long history dating back to its founding in 1921, a broad, globally scaled portfolio spanning drugs and health beverages, and a focus on health improvements across populations. Its stated goal is to create new products for better health worldwide.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Tokyo, Japan

Founded

1921

Get referred to Otsuka Pharmaceutical

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Otsuka closed Transcend in June 2026, expanding psychiatry beyond Abilify dependence.
  • DAWNZERA gained EU authorization in January 2026, opening paid sales across 27 countries.
  • Paradise uRDN and CART BP pro broaden Japan's hypertension platform and device distribution.

What critics are saying

  • SIMTRIYO waits on DEA scheduling, delaying revenue until late 2026.
  • VOYXACT's accelerated approval depends on confirmatory kidney-outcome data; failure risks withdrawal.
  • Transcend's TSND-201 PTSD program remains clinical-stage, risking a $1.225 billion write-down.

What makes Otsuka Pharmaceutical unique

  • Otsuka pairs CNS, nephrology, and device assets across Japan, US, and Europe.
  • SIMTRIYO gives Otsuka a first-in-class ADHD stimulant franchise after July 2026 FDA approval.
  • DAWNZERA and VOYXACT anchor rare-disease pipelines with global reimbursement and accelerated paths.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Company Match

Tuition Reimbursement

Student Loan Assistance

Paid Holidays

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Associated Press
Jul 25th, 2026
FDA approves Otsuka's Simtriyo, first-in-class ADHD treatment for adults and children 6+

Otsuka Pharmaceutical has received FDA approval for SIMTRIYO (centanafadine), the first norepinephrine, dopamine, serotonin reuptake inhibitor for treating ADHD in adults and children aged six years and older weighing at least 20kg. The once-daily extended-release capsule will be available later this year following DEA scheduling. The approval is based on four Phase 3 clinical trials showing statistically significant improvements in ADHD symptoms compared to placebo, with benefits observed as early as week one. Common side effects include decreased appetite, nausea, rash, and headache. ADHD affects approximately 7 million children and 15.5 million adults in the US. The drug carries boxed warnings for suicidal ideation in pediatric patients and potential for abuse and addiction.

SonoThera
Jun 10th, 2026
SonoThera Closes Oversubscribed $125 Million Series B Financing to Advance Clinical Development of Ultrasound-Mediated Nonviral Genetic Medicines - SonoThera

SAN FRANCISCO–SonoThera, a biotechnology company developing next-generation genetic medicines to address the root causes of disease, today announced the closing of an oversubscribed $125 million Series B financing round to advance its lead programs in Duchenne muscular dystrophy (DMD) and autosomal dominant polycystic kidney disease (ADPKD) into the clinic and expand its pipeline of targeted, redosable genetic medicines.

Dealroom.co
Mar 27th, 2026
Transcend Therapeutics company information, funding & investors

Transcend Therapeutics, developing the next generation of psychoactive compounds for neuropsychiatry focused on patient access. Here you'll find information about their funding, investors and team.

Fierce Biotech
Mar 27th, 2026
Otsuka buys Transcend Therapeutics for $700M upfront in psychiatric drugs deal

Otsuka Pharmaceutical has acquired Transcend Therapeutics for $700 million upfront through its subsidiary Otsuka America, with potential milestone payments of up to $525 million. The deal gives Otsuka access to Transcend's MDMA analogue for psychiatric conditions currently in development.

Associated Press
Mar 25th, 2026
Otsuka's Voyxact shows 82.5% hematuria improvement in IgA nephropathy trial at 48 weeks

Otsuka presented new Phase 3 VISIONARY trial data for VOYXACT (sibeprenlimab-szsi) in IgA nephropathy patients at the 2026 ISN World Congress of Nephrology. The analyses showed 82.5% of patients receiving sibeprenlimab achieved negative microscopic hematuria at week 48, compared with 52.6% on placebo. Median time to achieve hematuria negativity was nine weeks versus 24 weeks for placebo. VOYXACT, approved under accelerated approval in the US, is a monoclonal antibody that inhibits APRIL, a key driver in IgAN pathogenesis. Previously reported data showed the drug met its primary endpoint with a 51.2% placebo-adjusted reduction in proteinuria at nine months. The trial continues evaluating sibeprenlimab's effect on preserving kidney function over 24 months.